Background The risk of arterial thrombotic events (ATEs) is high among patients on systemic
anticancer therapies. Despite the efficacy of anticoagulants in the prevention of cancer …

Societal guidelines addressing the prevention of venous thromboembolism (VTE) in
ambulatory patients with cancer are numerous [1]. The need for guidelines is driven by an …

Background: Clinical practice guidelines recommend indefinite anticoagulation for a first
unprovoked venous thromboembolism (VTE). Objective: To estimate the benefit–harm …

Introduction There is limited evidence to inform thromboprophylaxis use for patients
receiving neoadjuvant chemotherapy prior to surgery in bladder cancer. We sought to …

Cancer patients represent a growing population with drastically difficult care and a lowered
quality of life, especially due to the heightened risk of vast complications. Thus, it is well …

Cancer-associated Thrombosis (CAT) is a common complication among patients with
cancer which is associated with significant morbidity and mortality. The risk of CAT varies …

Background Apixaban and rivaroxaban are two direct-acting oral anticoagulants (DOACs)
recommended for thromboprophylaxis in cancer patients treated with chemotherapy in an …

Third, public drug plans could regularly audit prescribing to identify patterns that indicate
large-scale nonadherence to restricted prescribing criteria, thereby triggering a review of …

Disclosures: Received honoraria from AstraZeneca for work on the regional clinical protocol
for the reversal of direct oral anticoagulants in patients with major bleeding. Mitigating …

Il y a peu de possibilités de modifier ces décisions une fois qu'elles ont été prises. Un
fabricant pharmaceutique peut demander d'ajouter des indications pour un médicament si …